January 6, 2020 10:51 AM ESTUpdated January 7, 05:10 PM
People

'U snooze u lose': Judg­ment day for $100M biotech in­sid­er trad­ing scheme looms as son of for­mer Ari­ad di­rec­tor stands tri­al

Amber Tong

A crim­i­nal tri­al that be­gins to­day in Man­hat­tan promis­es to un­rav­el a glob­al in­sid­er trad­ing ring that prof­it­ed off of non-pub­lic in­for­ma­tion about mul­ti­ple biotechs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times